Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04096638
Title	Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Spring Bank Pharmaceuticals, Inc.
Indications	melanoma hypopharynx cancer oral squamous cell carcinoma ovarian carcinoma Merkel cell carcinoma laryngeal squamous cell carcinoma Advanced Solid Tumor endometrial cancer lung non-small cell carcinoma renal cell carcinoma triple-receptor negative breast cancer head and neck squamous cell carcinoma transitional cell carcinoma stomach carcinoma oropharynx cancer hepatocellular carcinoma colorectal carcinoma cervical cancer
Therapies	Nivolumab + SB 11285 SB 11285
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
Fox Chase Cancer Center		Philadelphia	Pennsylvania	19111	United States	Details
UPMC Hillman Cancer Center		Pittsburgh	Pennsylvania	15232	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field